The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is closely associated with liver fibrosis. Hepatic stellate cells (HSC) and cancer-associated myofibroblasts are key players in liver fibrogenesis and hepatocarcinogenesis. Overexpression of fibroblast growth factor (FGF) receptors contributes to HCC development and progression. This study aimed to elucidate the role of FGFs in the HSC-HCC crosstalk. Analysis of the expression of the fifteen paracrine FGF-members revealed that FGF9 was only expressed by HSC but not by HCC cells. Also in human HCC tissues, HSC/stromal myofibroblasts were identified as cellular source of FGF9. High expression levels of FGF9 significantly correlated with poor patient survival. Stimulation with recombinant FGF9 induced ERK- and JNK-activation combined with significantly enhanced proliferation, clonogenicity, and migration of HCC cells. Moreover, FGF9 significantly reduced the sensitivity of HCC cells against sorafenib. Protumorigenic effects of FGF9 on HCC cells were almost completely abrogated by the FGFR1/2/3 inhibitor BGJ398, while the selective FGFR4 inhibitor BLU9931 had no significant effect. In conclusion, these data indicate that stroma-derived FGF9 promotes tumorigenicity and sorafenib resistance of HCC cells and FGF9 overexpression correlates with poor prognosis in HCC patients. Herewith, FGF9 appears as potential prognostic marker and novel therapeutic target in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas HSC-to-macrophage communication involved fibroblast growth factor (FGF)9 (ref. 49) signaling (characteristic of activated HSCs) to promote the profibrotic macrophage phenotype (Fig. 8c).”
From Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis (2025) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-5-642_1 · Cited by 2,087
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Aguirre-Gamboa, R., Gomez-Rueda, H., Martínez-Ledesma, E., Martínez-Torteya, A., Chacolla-Huaringa, R., Rodriguez-Barrientos, A., Tamez-Peña, J. G., & Treviño, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074250 · Cited by 686
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Katoh, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 412
Baglieri, J., Brenner, D. A., & Kisseleva, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071723 · Cited by 341
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma
Amann, T., Bataille, F., Spruß, T., Mühlbauer, M., Gäbele, E., Schölmerich, J., Kiefer, P., Bosserhoff, A., & Hellerbrand, C. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01087.x · Cited by 282
Self-citationHendrix, N. D., WU, R. T., Kuick, R. D., Schwartz, D. R., Fearon, E. R., & Cho, K. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3694 · Cited by 278
Cited by
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Huang, M., Lin, Y., Wang, C., Deng, L., Chen, M., Assaraf, Y. G., Chen, Z., Ye, W., & Zhang, D. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100849 · Cited by 185
Hepatic Stellate Cells and Hepatocarcinogenesis
Barry, A. E., Baldeosingh, R., Lamm, R. J., Patel, K., Zhang, K., Dominguez, D. A., Kirton, K. J., Shah, A. P., & Dang, H. T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00709 · Cited by 160
New developments in the biology of fibroblast growth factors
Ornitz, D. M., & Itoh, N. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1549 · Cited by 149
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Ferguson, H. R., Smith, M. P., & Francavilla, C. (2021) · Cells · doi:10.3390/cells10051201 · Cited by 143
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Qin, Y., Han, S., Yu, Y., Ding, Q., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.15953 · Cited by 110
Metadata
- Authors
- Seitz, T., Freese, K., Dietrich, P., Thasler, W. E., Bosserhoff, A., & Hellerbrand, C.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Hellerbrand, Claus
- Venue
- Scientific Reports
- Published
- 2020-03-11
- Volume
- 10
- Issue
- 1
- Pages
- 4546-4546
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7066162
- OpenAlex
- W3010669019
- Cited by
- 47
- References
- 38
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 11 · 2021: 11 · 2020: 6
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (HE2458/18, HE2458/15, HE2458/15 and HE2458/18)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- FGF9, hepatocellular carcinoma, hepatic stellate cells, liver fibrosis, cancer-associated myofibroblasts, tumor microenvironment, FGFR signaling, sorafenib resistance, BGJ398, FGFR4, ERK activation, JNK activation, tumor cell proliferation and migration, prognostic factors, therapeutic target
- MeSH terms
- Acrylamides, Cell Movement, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Prognosis, Quinazolines, Tumor Cells, Cultured, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Survival Rate, Apoptosis, Cell Proliferation, Receptor, Fibroblast Growth Factor, Type 4, Fibroblast Growth Factor 9, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41598-020-61510-4
- The paper
- Seitz, T., Freese, K., Dietrich, P., Thasler, W. E., Bosserhoff, A., & Hellerbrand, C. (2020). Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. Scientific Reports. https://doi.org/10.1038/s41598-020-61510-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.